Ze Jing Pharmaceutical (688266.SH): Injectable human thyroid stimulating hormone approved to be listed on the market.

17:26 08/01/2026

Zejing Pharmaceuticals (688266.SH) announced that on January 8, 2026, the company received the "Drug Registration Certificate" approved and issued by the National Medical Products Administration. The company's independently developed injection of human thyroid stimulating hormone (formerly known as injection of recombinant human thyroid stimulating hormone, trademark: Zesuning) has been approved for market application. The approved indication for this approval is: "Used for the collaborative diagnosis of differentiated thyroid cancer patients during follow-up after total or near-total thyroidectomy, for serum thyroid globulin (Tg) testing with or without radioactive iodine (131I) whole body scan (WBS) examination." Injection of human thyroid stimulating hormone is the first innovative product approved in China for precise assessment of differentiated thyroid cancer after surgery.

Zejing Pharmaceuticals (688266.SH) announced on January 8, 2026, that the company received the "Drug Registration Certificate" approved and issued by the National Medical Products Administration. The company's independently developed new drug, injection of recombinant human thyroid stimulating hormone beta (formerly known as injection of recombinant human thyroid stimulating hormone, trademark: Zesuning), has been approved for market application. The approved indication for this product is: "Used for the collaborative diagnosis of differentiated thyroid cancer patients in the follow-up after total or near-total thyroidectomy, to conduct serum thyroglobulin (Tg) testing, with or without radioactive iodine (131I) whole-body scan (WBS) examination." The injection of recombinant human thyroid stimulating hormone beta is the first innovative product approved in China for accurate assessment of differentiated thyroid cancer after surgery.

HK Stock Market Move | YIDU TECH (02158) rose more than 6% in the final trading session. The company is partnering with Peking University Hospital to establish a key experimental laboratory in Beijing, reshaping specialist medical decision making with AI.

A share closing review | The Shanghai Composite Index stabilizes at 4100 points, recording 16 consecutive gains! Trading volume surpasses 3 trillion for the fifth time in history.

Industrial: The Hang Seng Stock Connect is about to undergo a new round of adjustments, with 48 Hong Kong stock targets possibly being included.

A share closing review | The Shanghai Composite Index stabilizes at 4100 points, recording 16 consecutive gains! Trading volume surpasses 3 trillion for the fifth time in history.

Industrial: The Hang Seng Stock Connect is about to undergo a new round of adjustments, with 48 Hong Kong stock targets possibly being included.